Tesamorelin vs Sermorelin research in Canada compares these two GHRH receptor agonists for their structural differences, pharmacokinetic profiles, and differential research applications in GH axis biology. Sermorelin is GHRH(1-29) NH2 — the minimal bioactive fragment of endogenous GHRH — producing short-duration, physiologically pulsatile GHRH receptor activation. Tesamorelin is a synthetic full-length GHRH(1-44) analogue conjugated with Trans-3-hexenoic acid at the N-terminus, conferring dramatically increased protease resistance and extended biological activity compared to sermorelin. Canadian neuroendocrinology and metabolic researchers use both to study GHRH receptor pharmacology and adipose tissue GH signalling.
Structural and Pharmacokinetic Research
Sermorelin’s 1-29 fragment retains full GHRH receptor binding capacity but lacks the C-terminal stability of full-length GHRH, producing a plasma half-life of 10-20 minutes. Tesamorelin’s Trans-3-hexenoic acid N-terminal conjugation protects against DPP-4 and other protease cleavage at the Tyr1 position, extending biological activity. Canadian peptide pharmacokinetics researchers use both to study how N-terminal modifications translate to changes in GH pulse duration and somatotroph receptor kinetics.
Adipose Tissue Research
Tesamorelin is specifically studied for visceral adipose tissue reduction effects mediated through hepatic and adipose GH receptor signalling and downstream lipolysis pathway activation. Canadian metabolic biology researchers use Tesamorelin to study the GH axis–visceral fat biology interface, while Sermorelin is typically used for studying GH pulse physiology without specific adipose targeting focus.
Sourcing Tesamorelin and Sermorelin in Canada
Research-grade Tesamorelin and Sermorelin are available from EhBuddy Peptides in Canada. For laboratory research use only.
